Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by prophetoffactzon Mar 14, 2024 11:57am
80 Views
Post# 35932835

S&P Biotech ETF

S&P Biotech ETFS&P Biotech ETF is suddenly down about 9% from its high within the last month. Did Gilles manage to secure cash with the merger ahead of a potential inflation scare that could crush biotech stocks once again? The markets were expecting declining inflation and interest rates which is good for pre-revenue biotech. Was the market wrong as inflation data has been disapoining to the upside? CZO needs a well targeted investment program to make sure it leads to sustainability until the inflation issue is resolved.


 @PeterSchiff
Both bond yields and #oil prices are on the rise. 30-year yields are back above 4.4% headed to 5% and oil is back above $80 headed to $100. These trends fly in the face of the #Fed excepting to hit its 2% #inflation target and its intention to substantially reduce interest rates.

<< Previous
Bullboard Posts
Next >>